Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
0 ₽
0 products
All journals
Journal
Year
Year
Search result: 0

M.V. Zamergrad

V.A. Parfenov

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova, Moskva

E.I. Matsnev

Institute Medical and Biology Problem, Moscow, Russia

S.V. Morozova

Kafedra bolezneĭ ukha, gorla i nosa GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova", Moskva

O.A. Melnikov

GUTA CLINIC, Moscow

E.E. Sigaleva

Institute Medical and Biology Problem, Moscow, Russia

L.M. Antonenko

Sechenov First Moscow State Medical University, Moscow, Russia

Seven principles in the treatment of vestibular vertigo and results of the study of VIRTUOSO

Authors:

M.V. Zamergrad, V.A. Parfenov, E.I. Matsnev, S.V. Morozova, O.A. Melnikov, E.E. Sigaleva, L.M. Antonenko

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(12): 106‑110

DOI: 10.17116/jnevro2017117121106-110

Views: 55838

Downloaded: 437

Download PDF (RU)
Contact the author
Table of contents

SEVEN PRINCIPLES IN THE TREATMENT OF VESTIBULAR VERTIGO AND RESULTS OF THE STUDY OF VIRTUOSO
SEVEN PRINCIPLES IN THE TREATMENT OF VESTIBULAR VERTIGO AND RESULTS OF THE STUDY OF VIRTUOSO

To cite this article:

Zamergrad MV, Parfenov VA, Matsnev EI, Morozova SV, Melnikov OA, Sigaleva EE, Antonenko LM. Seven principles in the treatment of vestibular vertigo and results of the study of VIRTUOSO. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(12):106‑110. (In Russ.)
https://doi.org/10.17116/jnevro2017117121106-110

Здоровье щитовидной железы – 2024
Перекрестки терапевтических проблем
Доказательная гастроэнтерология: pro et contra
Актуальные вопросы педиатрической практики
Подписка 2024, 2 полугодие
NN - давайте знакомится (08.04.2024)
Использование инфографики авторами научных работ
МСФ на ЯМ
Mediasphera_Net
1med.tv
Close metadata
Recommended articles:
Treatment of diseases with consequences of traumatic brain injury. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3):26-33
Asthenic post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3):61-69
Features of treatment and reha­bilitation of COVID-19 patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3-2):76-84
Bila­teral peri­pheral vestibulopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(4):24-30
Features of the psychoemotional sphere and quality of life of patients with vestibular migraine. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(4):48-52
Opti­mization of treatment of depression with admi­nistration of ethy­lmethylhydroxypyridine succinate (Mexicor). S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(4):78-84
Chro­nic maxi­llary atelectasis or silent sinus syndrome. Russian Rhinology. 2023;(1):60-65
Diagnosis and treatment of orofacial pain syndromes. Russian Journal of Pain. 2023;(1):5-12
A case of Norwegian scabies in a mental defi­ciency. Russian Journal of Clinical Dermatology and Vene­reology. 2023;(2):161-164
Modern approaches to the treatment of ante­rior capsule contraction syndrome. Russian Annals of Ophthalmology. 2023;(2):89-94

This article reports the results of the international post-marketing observational program VIRTUOSO aimed at the evaluation of the efficacy of betahistine dihydrochloride at the dose of 48 mg/day for 1—2 months in patients with paroxysmal vertigo of various origins. The clinical response was rated as good, very good or excellent in 74.1% of the patients (p<0.001). Monthly vertigo attack frequency with betahistine decreased in average from 8.0 to 3.0 (p<0.001). Vertigo attack frequency further decreased during the 2-month follow-up after the end of betahistine treatment. No serious adverse effects of betahistine have been reported.

Keywords:

vertigo
treatment
vestibular rehabilitation
betahistine dihydrochloride
VIRTUOSO

Authors:

M.V. Zamergrad

V.A. Parfenov

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova, Moskva

E.I. Matsnev

Institute Medical and Biology Problem, Moscow, Russia

S.V. Morozova

Kafedra bolezneĭ ukha, gorla i nosa GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova", Moskva

O.A. Melnikov

GUTA CLINIC, Moscow

E.E. Sigaleva

Institute Medical and Biology Problem, Moscow, Russia

L.M. Antonenko

Sechenov First Moscow State Medical University, Moscow, Russia

List of references:

  1. Neuhauser HK, Lempert T. Vertigo: epidemiologic aspects. Semin Neurol. 2009;29(5):473-481.
  2. Hain TC, Uddin M. Pharmacological treatment of vertigo. CNS Drugs. 2003;17(2):85-100.
  3. Chabbert C. Principles of vestibular pharmacotherapy. Handb Clin Neurol. 2016;137:207-218. https://doi.org/10.1016/B978-0-444-63437-5.00014-5
  4. Brandt T. Vertigo. Its Multicensory Syndromes. London: Springer; 2000.
  5. Amini A, Heidari K, Asadollahi S, Habibi T, Shahrami A, Mansouri B, Kariman H. Intravenous promethazine versus lorazepam for the treatment of peripheral vertigo in the emergency department: A double blind, randomized clinical trial of efficacy and safety. J Vestib Res. 2014;24(1):39-47. https://doi.org/10.3233/VES-130506
  6. Ferber-Viart C, Dubreuil C, Vidal PP. Effects of acetyl-DL-leucine in vestibular patients: a clinical study following neurotomy and labyrinthectomy. Audiol Neurootol. 2009;14(1):17-25. https://doi.org/10.1159/000148206.
  7. Kalla R, Teufel J, Feil K, Muth C, Strupp M. Update on the pharmacotherapy of cerebellar and central vestibular disorders. J Neurol. 2016;263(1): 24-29. https://doi.org/10.1007/s00415-015-7987-x
  8. Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33:429-440.
  9. Venail F, Biboulet R, Mondain M A protective effect of 5-HT3 antagonist against vestibular deficit? Metoclopramide versus ondansetron at the early stage of vestibular neuritis: A pilot study. Eur Ann Otorhinolaryngol Head Neck Dis. 2012;129(2):65-68.
  10. Shepard NT, Telian SA. Programmatic vestibular rehabilitation. Otolaryngol Head Neck Surg. 1995;112:173-182.
  11. Rascol O, Hain TC, Brefel C, Benazet M, Clanet M, Montastruc JL. Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs. 1995;50(5):777-791.
  12. Zee DS. Perspectives on the pharmacotherapy of vertigo. Arch Otolaryngol. 1985;111(9):609-612.
  13. Xerri C, Lacour M. Compensation deficits in posture and kinetics following unilateral vestibular neurectomy in cats. The role of sensorimotor activity. Acta Otolaryngol. 1980;90(5-6):414-424.
  14. Zamergrad MV. Five Principles of Vestibular Rehabilitation. Effektivnaya farmakoterapiya. 2017;1:4-9. (In Russ.)
  15. Fernandes CM, Samuel J. The use of piracetam in vertigo. S Afr Med J. 1985;68:806-808.
  16. Hamann KF. Special ginkgo extract in cases of vertigo: a systematic review of randomised, double-blind, placebo controlled clinical examinations. HNO. 2007;55:258-263.
  17. Redon C, Lopez C, Bernard-Demanze L. Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. J Clin Pharmacol. 2011;51(4):538-548.
  18. Zamergrad MV, Parfenov VA, Yakhno NN. Optimal duration of therapy in the recovery period of vestibular diseases. Nevrologiya, neiropsikhiatriya i psikhosomatika. 2014;3:10-16.(In Russ.)
  19. Bhattacharyya N, Gubbels SP, Schwartz SR, Edlow JA, El-Kashlan H, Fife T, Holmberg JM, Mahoney K, Hollingsworth DB, Roberts R, Seidman MD, Steiner RW, Do BT, Voelker CC, Waguespack RW, Corrigan MD. Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update). Otolaryngol Head Neck Surg. 2017;156(3):1-47. https://doi.org/10.1177/0194599816689667
  20. Sagalovich BM, Pal’chun VT. Bolezn’ Men’era. M.: MIA; 1999. (In Russ.)
  21. Clyde JW, Oberman BS, Isildak H. Current Management Practices in Ménière’s Disease. Otol Neurotol. 2017;38(6):159-167. https://doi.org/10.1097/MAO.0000000000001421
  22. Nevoux J, Franco-Vidal V, Bouccara D, Parietti-Winkler C, Uziel A, Chays A, Dubernard X, Couloigner V, Darrouzet V, Mom T; Groupe de Travail de la SFORL. Diagnostic and therapeutic strategy in Menière’s disease. Guidelines of the French Otorhinolaryngology-Head and Neck Surgery Society (SFORL). Eur Ann Otorhinolaryngol Head Neck Dis. 2017;3:1879-7296(16)30222-8. https://doi.org/10.1016/j.anorl.2016.12.003
  23. Liu B, Leng Y, Zhou R, Liu J, Liu D, Zhang SL, Kong WJ. Intratympanic steroids injection is effective for the treatment of drop attacks with Ménière’s disease and delayed endolymphatic hydrops: A retrospective study. Medicine (Baltimore). 2016;95(52):5767. https://doi.org/10.1097/MD.0000000000005767
  24. Hegemann SCA, Wenzel A. Diagnosis and Treatment of Vestibular Neuritis/Neuronitis or Peripheral Vestibulopathy (PVP)? Open Questions and Possible Answers. Otol Neurotol. 2017;38(5):626-631. https://doi.org/10.1097/MAO.0000000000001396.
  25. Cassano D, Pizza V, Busillo V. Almotriptan in the acute treatment of Vestibular migraine: a retrospective study. J Headache Pain. 2015;16(1):114. https://doi.org/10.1186/1129-2377-16-S1-A114
  26. von Brevern M, Lempert T. Vestibular migraine. Handb Clin Neurol. 2016;137:301-316. https://doi.org/10.1016/B978-0-444-63437-5.00022-4
  27. Strupp M, Thurtell MJ, Shaikh AG Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus. J Neurol. 2011;258(7):1207-1222.
  28. Thurtell MJ, Leigh RJ. Treatment of nystagmus. Curr Treat Options Neurol. 2012;14(1):60-72.
  29. Lacour M. Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. J Vestib Res. 2013;23(3):139-151.
  30. Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo. Elucidation of mechanisms of action. CNS Drugs. 2001;15:853-870.
  31. Strupp M, Hupert D, Frenzel C, Wagner J, Hahn A, Jahn K, Zingler VC, Mansmann U, Brandt T. Long-term prophylactic treatment of attacks of vertigo in Menière’s disease comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol. 2008;128(5):520-524.
  32. Mira E, Guidetti G, Ghilardi L, Fattori B, Malannino N, Maiolino L, Mora R, Ottoboni S, Pagnini P, Leprini M, Pallestrini E, Passali D, Nuti D, Russolo M, Tirelli G, Simoncelli C, Brizi S, Vicini C, Frasconi P. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol. 2003;260(2):73-77.
  33. Lezius F, Adrion C, Mansmann U, Jahn K, Strupp M. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière’s disease: a case series. Eur Arch Otorhinolaryngol. 2011;268(8):1237-1240. https://doi.org/10.1007/s00405-011-1647-2
  34. Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M; BEMED Study Group. Efficacy and safety of betahistine treatment in patients with Meniere’s disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ. 2016;21:352:6816. https://doi.org/10.1136/bmj.h6816
  35. Parfenov VA, Golyk VA, Matsnev EI, Morozova SV, Melnikov OA, Antonenko LM, Sigaleva EE, Situkho MI, Asaulenko OI, Popovych VI, Zamergrad MV. Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study. PLoS One. 2017;30;12(3):0174114. eCollection 2017. https://doi.org/10.1371/journal.pone.0174114

Close metadata

Contact the author
Email
Message

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.